BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-891@pharmaconomics
DTSTAMP:20260707T033835Z
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260225
SUMMARY:PVLA Phase 3 — QTORIN 3.9% rapamycin anhydrous gel
DESCRIPTION:Phase 3 trial results for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations are due Feb 24\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-20260224.htm\n\nTrack it: https://pharmaconomics.com/e/891
URL:https://pharmaconomics.com/e/891
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PVLA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR